{"id":745181,"date":"2015-06-01T07:30:00","date_gmt":"2015-06-01T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/"},"modified":"2025-11-07T01:25:07","modified_gmt":"2025-11-07T06:25:07","slug":"merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/","title":{"rendered":"Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies"},"content":{"rendered":"<p class=\"bwalignc\">       Studies to Evaluate the Combination of Dynavax\u2019s SD-101 with Two        Immunotherapies from Merck\u2019s Pipeline, KEYTRUDA\u00ae (pembrolizumab) and        MK-1966     <\/p>\n<p class=\"bwalignc\">       Collaboration Includes First-in-human Study for MK-1966, a New        Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from        Merck\u2019s Rapidly Growing Immuno-oncology Pipeline     <\/p>\n<p>KENILWORTH, N.J. &amp; BERKELEY, Calif.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they<br \/>\n      have entered into two clinical trial collaboration agreements to<br \/>\n      investigate the potential synergistic effect of combining<br \/>\n      immunotherapies from both companies\u2019 pipelines: Merck\u2019s anti-PD-1<br \/>\n      therapy, KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), and its investigational<br \/>\n      anti-interleukin-10 (anti-IL-10) immunomodulator, MK-1966, with<br \/>\n      Dynavax\u2019s investigational toll-like receptor 9 (TLR9) agonist, SD-101.\n    <\/p>\n<p>\n      SD-101, KEYTRUDA, and MK-1966 are immunotherapies designed to enhance<br \/>\n      the body\u2019s own defenses in fighting cancer. SD-101 is designed to<br \/>\n      mediate anti-tumor effects by triggering both innate and adaptive immune<br \/>\n      responses, including the induction of high levels of Type 1 interferon<br \/>\n      to stimulate recruitment of T-cells. KEYTRUDA is a humanized monoclonal<br \/>\n      antibody that blocks the interaction between PD-1 (programmed death<br \/>\n      receptor-1) and its ligands, PD-L1 and PD-L2. MK-1966 is an<br \/>\n      investigational anti-IL-10 immunomodulator designed to neutralize the<br \/>\n      immune-suppressive environment for tumors. The collaboration includes<br \/>\n      multiple studies that will evaluate:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Safety and efficacy of combining SD-101 with KEYTRUDA<sup> <\/sup>in<br \/>\n        patients with advanced melanoma; this Phase 1b\/2, multicenter,<br \/>\n        open-label study is expected to be initiated in the second half of<br \/>\n        2015.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Safety and efficacy of combining SD-101 with MK-1966 in patients with<br \/>\n        solid or hematological malignancies; this Phase 1 study is expected to<br \/>\n        be initiated in the second half of 2015.\n      <\/li>\n<\/ul>\n<p>\n      \u201cThe collaboration with Dynavax is rooted in Merck\u2019s commitment to<br \/>\n      advancing breakthrough science in the field of immuno-oncology in order<br \/>\n      to address the complex interplay between the immune system and cancer,\u201d<br \/>\n      said Dr. Eric Rubin, vice president and therapeutic area head, oncology<br \/>\n      early stage development, Merck Research Laboratories. \u201cWe are pleased<br \/>\n      that this latest collaboration not only investigates the potential of<br \/>\n      KEYTRUDA as a combination therapy, but also includes our new<br \/>\n      immunomodulator candidate, MK-1966.\u201d\n    <\/p>\n<p>\n      \u201cOur interest in working with Merck on these clinical collaborations was<br \/>\n      propelled by the synergistic activity we have seen when SD-101 is<br \/>\n      combined with checkpoint inhibitors in preclinical models,\u201d said Eddie<br \/>\n      Gray, chief executive officer of Dynavax. \u201cThese collaborations with<br \/>\n      Merck will facilitate our objective to demonstrate SD-101\u2019s potential to<br \/>\n      complement multiple therapeutic modalities and thereby provide benefit<br \/>\n      to patients.\u201d\n    <\/p>\n<p>\n      Under the terms of the agreement, Dynavax will sponsor and fund the<br \/>\n      SD-101 and KEYTRUDA study. Merck will sponsor and fund the SD-101 and<br \/>\n      MK-1966 study. The agreements include provisions where the parties may<br \/>\n      agree to extend either collaboration to include a Phase 3 clinical<br \/>\n      trial. Additional details of the agreements between Dynavax and Merck,<br \/>\n      through a subsidiary, were not disclosed.\n    <\/p>\n<p>\n      <b>About SD-101<\/b>\n    <\/p>\n<p>\n      SD-101 is a proprietary, second-generation, TLR9 agonist CpG-C class<br \/>\n      oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of<br \/>\n      innate immune cells and activates plasmacytoid dendritic cells to<br \/>\n      stimulate T cells specific for antigens released from dying tumor cells.<br \/>\n      TLR9 agonists such as SD-101 enhance T and B cell responses and provide<br \/>\n      potent Type 1 interferon induction and maturation of plasmacytoid<br \/>\n      dendritic cells to antigen-presenting cells. SD-101 is being evaluated<br \/>\n      in several Phase 1\/2 oncology studies to assess its preliminary safety<br \/>\n      and activity.\n    <\/p>\n<p>\n      <b>About MK-1966<\/b>\n    <\/p>\n<p>\n      MK-1966, an investigational anti-interleukin-10 (anti-IL-10)<br \/>\n      immunomodulator, is designed to neutralize the immune-suppressive<br \/>\n      environment for tumors. MK-1966 blocks the activity of IL-10 which is<br \/>\n      known to down modulate the immune activation that is needed to kill<br \/>\n      tumor cells in the tumor microenvironment. These effects include<br \/>\n      decrease in cytokine production, upregulation of T regulatory cell<br \/>\n      activity and downregulation of antigen presenting cell activity. Based<br \/>\n      on preclinical data, co-administration of an anti-IL-10 with a TLR9<br \/>\n      agonist may provide clinical benefit in the treatment of certain cancers.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      Merck is advancing a broad and fast-growing clinical development program<br \/>\n      for KEYTRUDA with more than 100 clinical trials \u2013 across more than 30<br \/>\n      tumor types and enrolling more than 16,000 patients \u2013 both as a<br \/>\n      monotherapy and in combination with other therapies.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>About&nbsp;Dynavax<\/b>\n    <\/p>\n<p>\n      Dynavax, a clinical-stage biopharmaceutical company, discovers and<br \/>\n      develops novel vaccines and therapeutics in the areas of infectious and<br \/>\n      inflammatory diseases and oncology.&nbsp;Dynavax&#8217;s&nbsp;lead product candidates<br \/>\n      are HEPLISAV-B\u2122, a Phase 3 investigational adult hepatitis B vaccine and<br \/>\n      SD-101, an investigational cancer immunotherapeutic currently in several<br \/>\n      Phase 1\/2 studies. For more information visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dynavax.com&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=www.dynavax.com&amp;index=1&amp;md5=711b1e56d6a8be6569bfff6d50b7db00\" rel=\"nofollow\">www.dynavax.com<\/a>.\n    <\/p>\n<p>\n      <b>Dynavax Forward Looking Statements<\/b>\n    <\/p>\n<p>\n      This press release contains &#8220;forward-looking&#8221; statements, including<br \/>\n      expectations for the conduct and timing of clinical trials of SD-101.<br \/>\n      Actual results may differ materially from those set forth in this press<br \/>\n      release due to the risks and uncertainties inherent in our business,<br \/>\n      including whether we can timely provide adequate clinical supplies,<br \/>\n      initiate one or more studies, enroll a sufficient number of subjects and<br \/>\n      ultimately complete any study, and whether or not the parties may reach<br \/>\n      any future agreement on further studies or a more extensive<br \/>\n      collaboration beyond the clinical trials contemplated under the existing<br \/>\n      agreements, as well as other risks detailed in the &#8220;Risk Factors&#8221;<br \/>\n      section of our current periodic reports with the&nbsp;SEC. We undertake no<br \/>\n      obligation to revise or update information herein to reflect events or<br \/>\n      circumstances in the future, even if new information becomes available.<br \/>\n      Information on&nbsp;Dynavax&#8217;s&nbsp;website at&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dynavax.com&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=www.dynavax.com&amp;index=2&amp;md5=abd72f2fb4fc657f88f5d9aa28baeeb0\" rel=\"nofollow\">www.dynavax.com<\/a>&nbsp;is<br \/>\n      not incorporated by reference in our current periodic reports with<br \/>\n      the&nbsp;SEC.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment.&nbsp;Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=3&amp;md5=a9b7d848acaaaf0605e20be9be99f13f\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=4af812443c2cd082d5af074edfc5e401\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=d7a0ea99eeb5d832e2137da92bf1164f\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=abb52242c9fd12879e9017326fa63218\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=750aeaf132445da4a9c4f6c0b8a819e4\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=d1d6f6e0d9616b23e0d54205cdaf2e45\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=f6b5c74daa0a2887ab6851ba624c7579\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51114130&amp;newsitemid=20150601005806&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=3badf96d4e78cd9613df85265fa445c0\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150601005806r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck Media Relations:<br \/>Pamela Eisele, 267-664-0282<br \/>Claire        Mulhearn, 908-200-1889<br \/>or<br \/>Merck Investor Relations:<br \/>Justin        Holko, 908-740-1879<br \/>or<br \/>Dynavax Investor\/Media Relations:<br \/>Michael        Ostrach, 510-665-7257     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they have entered into two clinical trial collaboration agreements to investigate the potential synergistic effect of combining immunotherapies from both companies\u2019 pipelines: Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab), and its investigational anti-interleukin-10 (anti-IL-10) immunomodulator, MK-1966, with Dynavax\u2019s investigational toll-like receptor 9 (TLR9) agonist, SD-101. SD-101, KEYTRUDA, and MK-1966 are immunotherapies designed to enhance the body\u2019s own defenses in fighting cancer. SD-101 is designed to mediate anti-tumor effects by triggering both innate and adaptive immune responses, including the induction of high levels of Type 1 interferon to stimulate recruitment of T-cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289,56],"class_list":["post-745181","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they have entered into two clinical trial collaboration agreements to investigate the potential synergistic effect of combining immunotherapies from both companies\u2019 pipelines: Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab), and its investigational anti-interleukin-10 (anti-IL-10) immunomodulator, MK-1966, with Dynavax\u2019s investigational toll-like receptor 9 (TLR9) agonist, SD-101. SD-101, KEYTRUDA, and MK-1966 are immunotherapies designed to enhance the body\u2019s own defenses in fighting cancer. SD-101 is designed to mediate anti-tumor effects by triggering both innate and adaptive immune responses, including the induction of high levels of Type 1 interferon to stimulate recruitment of T-cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\\\/\",\"name\":\"Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-06-01T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Dynavax Technologies Corporation (Nasdaq: DVAX) today announced they have entered into two clinical trial collaboration agreements to investigate the potential synergistic effect of combining immunotherapies from both companies\u2019 pipelines: Merck\u2019s anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab), and its investigational anti-interleukin-10 (anti-IL-10) immunomodulator, MK-1966, with Dynavax\u2019s investigational toll-like receptor 9 (TLR9) agonist, SD-101. SD-101, KEYTRUDA, and MK-1966 are immunotherapies designed to enhance the body\u2019s own defenses in fighting cancer. SD-101 is designed to mediate anti-tumor effects by triggering both innate and adaptive immune responses, including the induction of high levels of Type 1 interferon to stimulate recruitment of T-cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:07+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/","name":"Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-06-01T07:30:00+00:00","dateModified":"2025-11-07T06:25:07+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-dynavax-announce-new-collaboration-investigating-the-combination-of-immuno-oncology-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"c913b7c3-66cf-4369-a1bf-65cdb23fa84d","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/06\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/06\/1\/Dynavax_Logo.jpg","size":"335543","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Dynavax-Announce-New-Collaboration-Investigating-the-Combination-of-Immuno-Oncology-Therapies-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745181\/revisions"}],"predecessor-version":[{"id":3674633,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745181\/revisions\/3674633"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745181"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}